Literature DB >> 12385010

The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia.

Ruud L M Bekkers1, Willem J G Melchers, Judith M J E Bakkers, Antonius G J M Hanselaar, Wim G V Quint, Henk Boonstra, Leon F A G Massuger.   

Abstract

We assessed prospectively whether residual cervical intraepithelial neoplasia (CIN) after treatment for high-grade CIN can be predicted by genotype-specific high-risk HPV (HR-HPV) detection in follow-up cervical scrapes. A broad spectrum, highly sensitive SPF(10)-LiPA-PCR HPV detection technique was used on cervical scrapes before large loop excision of the transformation zone (LLETZ), on the LLETZ biopsy and on follow-up scrapes of 90 patients treated for high-grade CIN. HR-HPV was detected in the biopsies of 93% (n = 84) of the patients and in the follow-up scrapes of 48% (n = 43) of the patients. In 12 patients, genotype-specific HR-HPV persistence was detected in both follow-up scrapes. In 10 patients, residual CIN was detected. In 5 of these patients (including all patients with residual CIN 3), the follow-up scrapes showed genotype-specific HR-HPV persistence. In 2 patients, a different HR-HPV was detected, and 3 patients had HR-HPV-negative follow-up scrapes. Conventional cytologic follow-up was abnormal in 13 patients including all 10 patients with residual CIN. The negative predictive value (NPV) of HR-HPV detection on follow-up scrapes was high (94%). Repeat detection of genotype-specific HR-HPV showed a lower sensitivity and NPV than repeat detection of any HR-HPV, but its specificity was higher. Repeat conventional cytologic follow-up showed the highest sensitivity and NPV. In conclusion, the presence of HR-HPV in cervical scrapes after LLETZ for high-grade CIN is a risk factor for the presence of residual CIN. HR-HPV genotype-specific persistence is specifically present in patients with residual CIN 3. However, HR-HPV detection cannot predict or exclude the presence of residual CIN in the individual patient and additional procedures remain necessary. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12385010     DOI: 10.1002/ijc.10691

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test.

Authors:  Matthew P Stevens; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

Review 2.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

3.  Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests.

Authors:  Matthew P Stevens; Elice Rudland; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 4.  Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.

Authors:  Sarah R Hoffman; Tam Le; Alexandre Lockhart; Ayodeji Sanusi; Leila Dal Santo; Meagan Davis; Dana A McKinney; Meagan Brown; Charles Poole; Corinne Willame; Jennifer S Smith
Journal:  Int J Cancer       Date:  2017-02-27       Impact factor: 7.396

5.  Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?

Authors:  Björn Strander; Walter Ryd; Keng-Ling Wallin; Bengt Wärleby; Biying Zheng; Ian Milsom; Baback Gharizadeh; Nader Pourmand; Agneta Andersson-Ellström
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

Review 6.  Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.

Authors:  Benjamin K S Chan; Joy Melnikow; Christina A Slee; Rose Arellanes; George F Sawaya
Journal:  Am J Obstet Gynecol       Date:  2009-01-24       Impact factor: 8.661

7.  Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.

Authors:  Mamiko Onuki; Koji Matsumoto; Manabu Sakurai; Hiroyuki Ochi; Takeo Minaguchi; Toyomi Satoh; Hiroyuki Yoshikawa
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

Review 8.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

9.  Coexisting high-grade glandular and squamous cervical lesions and human papillomavirus infections.

Authors:  R L M Bekkers; J Bulten; A Wiersma-van Tilburg; M Mravunac; C P T Schijf; L F A G Massuger; W G V Quint; W J G Melchers
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.